Effects of Clopidogrel on Blood Pressure

University of Cologne

Status and phase: Completed; Phase 4

Conditions: Endothelial Function; Platelet Function; Blood Pressure

Treatments: Drug: Clopidogrel

Study type: Interventional

Funder types: Other

Identifiers

NCT01112137

NLN5031

Details and patient eligibility

About

Context: Soluble CD40 ligand (sCD40L) released from activated platelets induces inflammatory transformation of the vascular endothelium and is an independent predictor of cardiovascular events. Arterial hypertension is associated with platelet activation, increased sCD40L levels and endothelial dysfunction suggesting that inhibition of platelet-derived sCD40L release may improve endothelial function and lower blood pressure (BP).

Objective: To determine the effects of clopidogrel on sCD40L, endothelial function and BP.

Design: Randomized, controlled, investigator-blinded, parallel-group, 2-phase trial in patients with coronary artery disease and essential arterial hypertension and those without hypertension.

Intervention: Participants receive a single 600-mg clopidogrel loading dose (phase I) followed by a daily 75-mg clopidogrel maintenance dose over 28 days (phase II).

Outcome Measures: Primary outcome measure is the change in BP from baseline. Secondary outcome measures are changes in biomarkers of platelet and endothelial function and their correlation with BP.

Enrollment: 46 patients

Sex: All

Ages: 45 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with coronary artery disease (CAD) and a clinical presentation of stable angina pectoris or acute coronary syndrome who had undergone percutaneous coronary intervention (PCI) with stent implantation
• 5-year history of essential arterial hypertension with a systolic BP between 140 and 170 mmHg or no hypertension (systolic BP <140mg Hg and diastolic BP <90 mmHg)
• treatment with clopidogrel (75 mg per day) for 6 to 12 months after PCI
• continuous use of aspirin (100 mg per day)
• no change in drug therapy within 3 months prestudy

Exclusion criteria

• stent thrombosis or another ischemic cardiovascular event following PCI
• use of other antiplatelet drugs or anticoagulants within 3 months prestudy
• surgery within 3 months prestudy
• arrhythmia
• valvular heart disease
• hematologic disorder
• severe renal disorder
• severe hepatic disorder
• chronic inflammatory disorder
• autoimmune disorder
• acute or chronic infection
• active malignancy
• a body-mass index below 18.5 or above 40 kg/m2
• nonadherence to therapy
• nonattendance to control visits

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

46 participants in 4 patient groups

Hypertensive individuals: clopidogrel (600 mg, bolus)

Experimental group

Treatment:

Drug: Clopidogrel

Drug: Clopidogrel

Drug: Clopidogrel

Drug: Clopidogrel

Hypertensive individuals: clopidogrel (75 mg daily)

Experimental group

Treatment:

Drug: Clopidogrel

Drug: Clopidogrel

Drug: Clopidogrel

Drug: Clopidogrel

Normotensive individuals: clopidogrel (600 mg, bolus)

Active Comparator group

Treatment:

Drug: Clopidogrel

Drug: Clopidogrel

Drug: Clopidogrel

Drug: Clopidogrel

Normotensive individuals: clopidogrel (75 mg, daily)

Active Comparator group

Treatment:

Drug: Clopidogrel

Drug: Clopidogrel

Drug: Clopidogrel

Drug: Clopidogrel